Endo International plc and Advanz Pharma Corp. Limited, a specialty pharmaceutical company, have announced that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl entity, a subsidiary of Advanz Pharma, to commercialize and distribute on an exclusive basis Xydalba (dalbavancin hydrochloride) in Canada.
Under the terms of the agreement, Endo Ventures Limited will be responsible for the distribution, sales, marketing, medical affairs, pricing and reimbursement activities in Canada. Endo Venture Limited's affiliate, Paladin Labs Inc., an operating company of Endo International plc, will perform those activities. Advanz Pharma will be responsible for supplying the drug. Paladin Labs is targeting to launch the product in 2021. Advanz Pharma will provide additional business updates as and when appropriate.
Xydalba was approved by Health Canada in September 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by susceptible isolates of gram-positive microorganisms, including methicillin resistant Staphylococcus aureus (MRSA).
Simon Tucker, chief commercial officer for established products at Advanz Pharma says: "Advanz Pharma is extremely excited about this new partnership. Paladin brings a deep knowledge of the Canadian market and the anti-infective segment and we are confident this will be a successful partnership."
Livio Di Francesco, vice president and general manager of Paladin says: "This launch will not only provide broader choice but also wider access. We are delighted to partner with Advanz Pharma to offer this important product to appropriate patients in Canada."
Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.
Advanz Pharma is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe.
